Long term visual outcomes in ranibizumab non-responders: patients with neovascular age-related macular degeneration switched from ranibizumab to aflibercept

被引：0
|
作者：
Afshar, Farid [1 ]
Fletcher, Emily [1 ]
Mohamed, Quresh [1 ]
Johnston, Rob [1 ]
机构：
[1] Cheltenham Gen Hosp, Ophthalmol, Eastleigh, England
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2016年 / 57卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
520
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Visual outcomes of eyes with neovascular age-related macular degeneration requiring frequent ranibizumab when switched to aflibercept
    Ellabban, Abdallah
    Sallam, Ahmed
    Petousis, Vasileios
    Fletcher, Emily
    Mohamed, Quresh
    Johnston, Robert
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [2] Short-Term Outcomes of Eyes with Neovascular Age-related Macular Degeneration (nAMD) that Switched from Aflibercept to Ranibizumab
    Hsu, Jason
    Obeid, Anthony
    Mellen, Phoebe L.
    Wibbelsman, Turner D.
    Konkoly, Michelle A.
    Velez, Michael R.
    Calem, Daniel B.
    Sioufi, Kareem
    Su, Daniel
    Storey, Philip
    Klufas, Michael A.
    Spirn, Marc J.
    Regillo, Carl
    Ho, Allen C.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [3] UK outcomes of switching patients with neovascular age-related macular degeneration from ranibizumab to aflibercept
    Manjunath, Vina
    Talks, James S.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [4] Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD)
    Otsuji, Tsuyoshi
    Nagai, Yoshimi
    Sho, Kenichiro
    Tsumura, Akiko
    Koike, Naoko
    Tsuda, Mei
    Nishimura, Tetsuya
    Takahashi, Kanji
    CLINICAL OPHTHALMOLOGY, 2013, 7 : 1487 - 1490
  • [5] Switching from ranibizumab and aflibercept to bevacizumab therapy in neovascular age-related macular degeneration patients
    Calugaru, Dan
    Calugaru, Mihai
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2020, 30 (05) : NP1 - NP2
  • [6] Ranibizumab for neovascular age-related macular degeneration
    Rosenfeld, Philip J.
    Brown, David M.
    Heier, Jeffrey S.
    Boyer, David S.
    Kaiser, Peter K.
    Chung, Carol Y.
    Kim, Robert Y.
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14): : 1419 - 1431
  • [7] Predictors of Outcome in Patients with Neovascular Age-Related Macular Degeneration Switched from Ranibizumab to 8-Weekly Aflibercept
    Chatziralli, Irini
    Nicholson, Luke
    Vrizidou, Eleni
    Koutsiouki, Chysoula
    Menon, Deepthy
    Sergentanis, Theodoros N.
    Citu, Maria Cristina
    Hamilton, Robin
    Patel, Praveen J.
    Hykin, Phil
    Sivaprasad, Sobha
    OPHTHALMOLOGY, 2016, 123 (08) : 1762 - 1770
  • [8] Retrospective analysis of patients with neovascular Age-related Macular Degeneration (nAMD) switched from ranibizumab to aflibercept and switched back to ranibizumab, using a treat and extend regimen
    Rumen, Franck
    Uzzan, Joel
    Oubraham, Hassiba
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [9] Ranibizumab for neovascular age-related macular degeneration
    Hernandez-Pastor, Luis Javier
    Ortega, Ana
    Garcia-Layana, Alfredo
    Giraldez, Joaquin
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2008, 65 (19) : 1805 - 1814
  • [10] Ranibizumab for neovascular age-related macular degeneration
    Gillies, Mark C.
    Wong, Tien Y.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (07): : 748 - 749
12345